Navigation Links
GeNO LLC Announces Senior Management Appointment
Date:8/27/2013

WALTHAM, Mass., Aug. 27, 2013 /PRNewswire/ -- GeNO LLC, a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases, today announced that Kurt A. Dasse, Ph.D., currently serving as president and a member of the company's Board of Managers, has been appointed CEO of the Company.  Dr. David Fine will continue to serve GeNO as executive chairman and chief scientific officer.

"Dr. Dasse has significant international experience with the use of inhaled nitric oxide to minimize the risk of right heart failure following the treatment of patients undergoing the implantation of Left Ventricular Assist Devices (LVADs). This appointment will strengthen the company's focus on developing and obtaining regulatory approvals for its innovative and cost-effective platforms for generating nitric oxide therapy in the treatment of multiple diseases and conditions," said David Fine, GeNO founder and executive chairman. "I am thrilled to hand over the role of CEO to Kurt."

"I believe GeNO is well positioned to make a significant impact on the medical treatment of patients worldwide who suffer from pulmonary and cardiac diseases," said Dasse. "I am honored and excited to lead a highly talented group at GeNO committed to delivering the next generation of inhaled nitric oxide products, including a portable solution, designed to benefit a large patient population."

Dasse, who will continue to serve on the company's Board of Managers, has spent nearly 30 years researching and developing therapies for cardiopulmonary disorders, and has developed and commercialized devices and therapies for the treatment of heart, lung and renal failure. He joined GeNO as a member of the Board of Managers in 2007, and was appointed executive vice president in 2011 and president in 2012.

In 2001 Dasse co-founded Levitronix LLC, the developer of the CentriMag LVAD system, where he became president and CEO in 2006. Earlier in his career, Dasse was chief scientist and vice president of Thermo Electron Corporation's $700-million Biomedical Group. He was also one of the founding officers of Thermo Cardiosystems and played a key role in commercializing one of the first implantable ventricular assist systems for end-stage heart failure patients. Dasse received his doctorate in physiology from Boston University and his bachelor's degree in biology from the University of Massachusetts. He has written more than 100 journal articles and multiple book chapters, and holds numerous patents.

ABOUT GENO LLC

GeNO LLC is a privately-held biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases.  GeNO is currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting.  GeNO's technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians and other end-users with a user-friendly solution.

CONTACT: Brian Heffron, bheffron@ctpboston.com
(781) 799-9568


'/>"/>
SOURCE GeNO LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sihuan Pharmaceutical Announces 2013 Interim Results
2. Echo Therapeutics Announces Management Changes
3. ConvaTec Announces 2013 Second Quarter Earnings Call
4. Sam Solakyan, CEO of Vital Imaging Announces purchase of cutting edge equipment
5. Yew Bio-Pharm Group Announces Coverage by S&P Capital IQ
6. Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
7. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
8. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
9. VirtualScopics Announces 1-for-10 Reverse Stock Split
10. Allscripts Announces Winners of the Open App Challenge
11. CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... NEW YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities ... New York City , announces that a ... of Massachusetts  against Inotek Pharmaceuticals ... purchasers of the Company,s securities between July 23, 2015 and ...
(Date:2/24/2017)... Australien, 24. Februar 2017 ITL Limited, ... des Gesundheitsbereiches, ist erfreut, für das zum 31. ... entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine ... zum Wachstum" finden Sie hier . ... nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  This report analyzes the worldwide markets for ... Products: Intermediates, Analytical, and Others. The End ... and Agrochemicals. The report provides separate comprehensive analytics for ... Europe , and Rest of World. Annual estimates ... 2022. Also, a six-year historic analysis is provided for ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Healthcare Associates of McKinney announced today that ... at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is in ... , As the practice has grown, the need for more space has been paramount. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
(Date:2/23/2017)... ... 2017 , ... Rare Disease Report®, which is the only ... Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on February ... e-newsletter and quarterly publication, will be conducting interviews with patients and advocates in ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
Breaking Medicine News(10 mins):